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Abstract:  2 
The prevalence of cardiometabolic diseases is a significant public health burden worldwide. 3 
Emerging evidence supports the inverse association between greater dairy consumption and 4 
reduced risk of cardiometabolic diseases. Dairy proteins may have in important role in the 5 
favourable impact of dairy on human health such as blood pressure (BP) control, blood lipid 6 
and glucose control. The purpose of this review is to update and critically evaluate the 7 
evidence on the impacts of casein and whey protein in relation to metabolic function. 8 
Evidence from acute clinical studies assessing postprandial responses to milk protein 9 
ingestion suggests benefits on vascular function independent of BP, as well as improvement 10 
in glycaemic homeostasis. Chronic interventions have been less conclusive, with some 11 
showing benefits and others indicating a lack of improvement in vascular function. During 12 
chronic consumption BP appears to be lowered and both dyslipidaemia and hyperglacaemia 13 
seems to be controlled. Limited number of trials investigated the effects of dairy proteins on 14 
oxidative stress and inflammation. The beneficial changes in cardiometabolic homeostasis are 15 
likely mediated through improvements in insulin resistance, however to gain more detailed 16 
understanding on the underlying mechanism of milk proteins warrants further research. The 17 
incorporation of meals enriched with dairy protein in the habitual diet may result in the 18 
beneficial effects on cardiometabolic health. Nevertheless, future well-designed, controlled 19 
studies are needed to investigate the relative effects of both casein and whey protein on BP, 20 
vascular function, glucose homeostasis and inflammation.  21 
22 
Introduction 23 
Milk and dairy products are widely consumed around the world on a daily basis. They are not 24 
only an important source of nutrients in the human diet, but also represent important value in 25 
the food chain providing opportunities for farmers, food processors, and retailers to contribute 26 
to increased food security and poverty alleviation poverty
(1)
. Therefore any change in milk 27 
and dairy consumption will have multiple impacts on human and animal health, environment, 28 
food security, and economics. Indeed, according to an OECD-FAO report, milk production is 29 
projected to increase by 180 million tonnes in the next decade, predominantly in developing 30 
countries
(2)
. Moreover, the inclusion of animal-derived products adds diversity to plant-based 31 
diets, providing an important source of many essential nutrients, the dietary requirements of 32 
which would be more difficult to meet by plant-based diets. However the potential health 33 
impacts of animal-derived foods, and more specifically milk and dairy consumption, have 34 
been questioned owing to their high saturated fat content, (for review, see:
(3)
). Yet, emerging 35 
epidemiological evidence supports the beneficial effects of milk and dairy consumption on 36 
health, particularly cardiometabolic health
(4-6)
.  37 
Milk is a complex food, a unique package of many nutrients such as calcium, magnesium, 38 
iodine, phosphorus, vitamin B12, pantothenic acid, riboflavin, high quality protein, peptides, 39 
and oligosaccharides. In the human body these bioactive components may interact with each 40 
other and exert synergistic effects, making it difficult to assign the specific health effect of a 41 
single component. Bovine milk, which is widely consumed around the world, contains 42 
approximately 32-34 g/L protein of which 80% (w/w) is casein and 20% (w/w) is whey 43 
protein. Both milk proteins consist of smaller protein fractions such as casein - alpha-s1, 44 
alpha-s2, beta and kappa-casein, and whey - beta-lactoglobulin, alpha-lactalbumin, 45 
lactoferrin, immunoglobulins, serum albumin, glycomacropeptide, enzymes and growth 46 
factors. Milk proteins are considered to be high quality proteins. Whey protein is rich in 47 
branched-chain amino acids (BCAA) such as leucine, isoleucine and valine, whilst casein 48 
contains more histidine, methionine, phenylalanine, proline, serine, tyrosine and valine. It is 49 
well established that casein and whey have differential effects on gastric emptying and 50 
kinetics of digestion and absorption
(7)
. Intact micellar casein clots in the stomach due to the 51 
low pH, and is, therefore, digested more slowly, which results in a prolonged and more 52 
sustained AA release. In contrast, intact whey (which is acid soluble) or hydrolysed whey and 53 
casein are absorbed more rapidly, with a slower AA release and half-life 
(7)
. It is, however, of 54 
note that micellar casein is different from Ca or Na caseinate (micellar casein is acidified and 55 
neutralised with alkali e.g. NaOH or Ca(OH)2 in order to form caseinate), as the latter are 56 
soluble and thus may show similarities to whey in terms of digestion rates
(8, 9)
. As a result of 57 
their different inherent AA compositions leading to distinct absorption and kinetic behaviour, 58 
they may also have differential effects on human health. 59 
The aim of this review is to update and critically evaluate the existing evidence on the effects 60 
of casein and whey on metabolic function, including blood pressure, vascular function, 61 
glucose and lipid metabolism, and inflammation. 62 
 63 
Comprehensive literature search 64 
A comprehensive literature search was conducted using the electronic databases MEDLINE, 65 
the Cochrane Library, EMBASE and Web of Science using the following terms: intervention, 66 
randomised controlled trials (RCT), clinical trials, high blood pressure, hypertension, anti-67 
hypert*, vascular function, endothelial function, vascular stiffness, milk protein, milk 68 
peptide*, casein, hydrolysate, humans, lipids, insulin, glucose, inflammation. Furthermore, 69 
hand-searching was performed on the reference lists of both studies and review articles. In 70 
addition, Google and Google Scholar were used to confirm that the search was complete. The 71 
search period covered studies published until September 2015.  72 
 73 
Blood pressure 74 
Cardiovascular diseases (CVD) remain the leading cause of death in most countries 75 
worldwide. In the UK there has been a significant decrease in death rates since 1961, and due 76 
to a combination of better healthcare and preventative strategies, in 2012 CVD became the 77 
second main cause of death (CVD caused 28% of all death and cancer 29%)
(10)
. 78 
Approximately seven million people live with CVD in the UK which costs £19 billion each 79 
year (including premature death, lost productivity, hospital treatment, prescriptions) resulting 80 
in a significant economic burden
(10)
. Premature death from CVD can be prevented by 81 
improving modifiable risk factors. For example, it has been estimated that in the general 82 
population increasing physical activity, smoking cessation and dietary changes can lead to 83 
50%, 20-30% and 15-40% mortality risk reduction, respectively
(11)
.  84 
High BP (hypertension) is the key modifiable risk factor of CVD and of stroke in particular. 85 
Nearly 30% of adults in the UK have high BP, however only half of them are aware of it and 86 
even less receive treatment
(10). High BP is present when systolic blood pressure (SBP) is ≥140 87 
mmHg and/or diastolic blood pressure (DBP) is ≥90 mmHg(12). It is important to treat 88 
hypertension and maintain BP in the normal range as elevated BP can cause irreversible 89 
damage to different organs such as kidneys, heart and eyes
(12)
.  90 
 91 
Long-term studies on blood pressure 92 
We have recently reviewed the evidence from RCTs on the antihypertensive effects of milk 93 
proteins and peptides
(13)
. For that review we systematically searched and reviewed the 94 
literature until December 2012. There was an imbalance in the literature as more RCTs were 95 
conducted using mainly one type of casein-derived peptides, called lactotripeptides (LTP). 96 
We, therefore conducted an updated meta-analysis on the impact of LTP on BP
(14)
, which 97 
included all available and relevant RCTs and detailed subgroup and regression analyses which 98 
were somewhat limited in previous meta-analyses in this area
(15-18)
. We found a small, but 99 
significant reduction in both SBP (−2.95 mmHg (95% CI: −4.17, −1.73; p < 0.001)) and 100 
DBP (−1.51 mmHg (95% CI: −2.21, −0.80; p < 0.001)) after four weeks of LTP 101 
supplementation in pre- and hypertensive populations. Since there was a statistically 102 
significant heterogeneity of treatment effects across studies, sub-group analyses were 103 
performed. These analyses suggested differences in countries where RCTs were conducted: 104 
Japanese studies reported significantly greater BP-lowering effect of LTP (-5.54 mmHg for 105 
SBP; and -3.01 mmHg for DBP), compared with European studies (-1.36 mmHg for SBP; and 106 
-0.83 mmHg for DBP; p=0.002 for SBP and <0.001 for DBP). This was confirmed in a recent 107 
meta-analysis which focused on Asian RCT only. However it only assessed SBP and the 108 
authors reported a very similar reduction of -5.63 mmHg in SBP as we found
(19)
. There may 109 
be several explanations for this observation. Firstly Japanese diets contains less milk and 110 
dairy products than European diets, therefore consumption of milk proteins may have a 111 
greater overall impact when compared to population that consume these proteins more 112 
regularly and in higher quantities
(20)
. Furthermore there are reported ethnic differences in the 113 
response to drug administration, BP-lowering in particular
(21)
 which could impact on the 114 
response to these bioactive proteins and finally differences in response may have resulted 115 
from different spatial conformations (cis/trans) of LTP used in the studies, due to production 116 
processes
(22)
. Intriguingly, we also found a “small-study effect”, and when all bias was 117 
considered it shifted the treatment effect towards a less significant SBP and non-significant 118 
DBP reduction in response to LTP supplementation. We concluded that with potential bias 119 
considered, LTP consumption may still be effective in lowering blood pressure in mildly 120 
hypertensive or hypertensive groups
(14)
.  121 
During our systematic literature search
(13)
 we found that there were very few studies 122 
investigating the BP-lowering effects of other casein-derived peptides in humans
(23-27)
. 123 
Furthermore these studies were limited, used different types of peptides and were often 124 
uncontrolled with poor methodological and study design. Due to these inconsistencies in 125 
study design, it was impossible to compare these data and no firm conclusion could be drawn 126 
on the antihypertensive effects of casein-derived peptides. Similarly, we found a limited 127 
number of RCTs conducted using intact whey or whey-derived peptides assessing their 128 
antihypertensive effects in humans
(28-33)
. These trials seems to be of higher quality than 129 
studies on casein-derived peptides, however the findings of these studies were also 130 
inconsistent
(13)
.  131 
Since our review, published in 2013, three new studies which assessed the effects of milk 132 
proteins on BP as primary outcome were published. Petyaev et al.
(34)
 examined the impacts of 133 
whey protein embedded in a protective lycopene matrix, a new proprietary formulation, so 134 
called whey protein lycosome, in a pilot study. Authors hypothesised that this formulation 135 
would protect whey protein from gastrointestinal degradation which would increase the 136 
bioavailability of the protein, and thus reduce the need for a high dose. They administered 70 137 
mg of whey protein along with 7 mg of lycopene in the form of a capsule (WPL) and 138 
compared this to whey protein (70 mg) and lycopene (7 mg) separately (taken once a day for a 139 
month). A significant decrease in BP (-7 mmHg in SBP and -4 mmHg in DBP, p<0.05) in the 140 
WPL group was reported compared to baseline only and no effect relative to the whey and 141 
lycopene given separately. Due to the nature of this pilot study, there was no information on 142 
blinding, the sample size was small (10/treatment group) and due to the limited statistical 143 
analysis further investigation is needed to evaluate the potential antihypertensive effect of 144 
WPL. Another RCT was conducted in overweight and obese adolescents (aged 12-15 years), 145 
who were asked to consume 1 litre/day of either water, skimmed milk, whey or casein (milk-146 
based treatment drink contained 35 g/L protein) for 12 weeks
(35)
. A decrease in brachial and 147 
central aortic DBP compared to baseline and control group (consuming water) was observed, 148 
whereas whey protein appeared to increase brachial and central aortic SBP, and central DBP. 149 
The authors acknowledged several limitations of the study, including difficulties in 150 
recruitment, changes in the research protocol after study commencement and not controlling 151 
for the extra energy intake that 1 litre/day treatment drinks provided, which led to an increase 152 
in weight in those in the treatment groups compared to a loss in the control group which 153 
consumed water. Therefore due to these limitations it was difficult to draw firm conclusions 154 
from these data. A study of Figueroa et al. examined the effects of both whey and casein on 155 
BP and vascular function combined with exercise training in obese, hypertensive women
(36)
. 156 
In their 4-week trial, participants were assigned to consume 30 g casein, whey or 34 g of 157 
maltodextrin (control) and perform resistance and endurance exercises 3 days/week under a 158 
qualified instructor’s supervision. They reported significant reduction in both brachial and 159 
aortic SBP in both whey and casein groups compared to control, although this was not 160 
observed for DBP. The exercise training did not have additional effects on BP or arterial 161 
function, owing the beneficial effect on the cardiovascular system to the milk proteins (Table 162 
1.). 163 
In summary, emerging evidence suggest that milk protein consumption for at least four weeks 164 
may result in small blood pressure lowering, however further well controlled studies 165 
involving 24-hour ambulatory blood pressure monitor should be performed for confirmation. 166 
 167 
Long-term studies on blood pressure 168 
According to a typical Western eating pattern, people spend up to 18h/day in a postprandial 169 
state consuming three or more meals daily. Furthermore elevated postprandial lipeamia, 170 
glycaemia and inflammation have been linked with increased risk for chronic disease 171 
development including diabetes and CVD
(37-39)
. Therefore dietary strategies that attenuate the 172 
postprandial metabolic disturbance are urgently required. 173 
To date only two studies have evaluated the acute effects of milk proteins on BP. Pal and Ellis 174 
compared 45 g whey protein isolate, 45 g Na-caseinate with 45 g glucose in conjunction with 175 
a breakfast in normotensive overweight and obese women
(32)
 but found no effect of treatment. 176 
A more recent study compared the postprandial effects of several dietary proteins (milk 177 
protein, pea protein and egg-white) and carbohydrate-rich meals on BP-related responses
(40)
. 178 
Although the authors failed to specify the specific type of milk protein isolate used, its BP-179 
lowering effect was not significantly different to pea protein, although both milk and pea 180 
protein were significantly lower than egg-white (p≤0.01) (Table 1.). The lack of evidence on 181 
the acute BP effects of milk proteins warrants further research .  182 
 183 
Vascular function 184 
Vascular dysfunction is often used as an umbrella term for abnormalities of the vascular 185 
system, such as endothelial dysfunction and arterial stiffness
(41)
. The endothelium, the inner 186 
layer of cells of the vasculature, plays a key regulatory role in the vascular system. Any 187 
disturbance in endothelial function, such as increased permeability, reduced vasodilation and 188 
activation of thrombotic and inflammatory pathways, can lead to atherosclerotic 189 
development
(42)
. Due to the central role of the endothelium in the development of 190 
atherosclerosis, several non-invasive methods have been developed to assess endothelial 191 
dysfunction. Nitric oxide plays a primary role in the control of vascular function and which is 192 
produced by the endothelium. Flow-mediated dilation (FMD) is considered to be the ‘gold 193 
standard’ method of assessing endothelial function and may surpass the predictive value of 194 
traditional risk factors such as smoking, elevated cholesterol level in predicting cardiovascular 195 
events in patients with established cardiovascular disease
(43)
.  However it is of note that this 196 
technique requires extensive training and is operator dependent, which may limit its value. 197 
Arterial stiffness is a measure of arterial elasticity which is the ability to expand and contract 198 
along with cardiac pulsation and relaxation. CVD risk factors such as ageing, hypertension, 199 
smoking and diet have been shown to have a detrimental effect on arterial distensibility, 200 
inducing an imbalance between the synthesis and degradation of elastin and type 1 and 3 201 
collagen
(44). Pulse wave velocity (PWV) is considered to be the ‘gold-standard’ to measure 202 
arterial stiffness and has a substantial predictive value for CVD events
(45)
.  203 
 204 
Long-term studies on vascular function 205 
Our previous review also evaluated the health effects of milk proteins and/or their peptides on 206 
vascular function
(13)
. In brief, we identified nine chronic RCTs
(33, 46-53)
, of which eight used 207 
lactotripeptides
(46-54)
 and one trial used intact casein and whey
(33)
. These studies were diverse 208 
in several aspects of methodologies such as design, length and dose of treatment, subject 209 
characteristics and measures of vascular function, and most importantly type of milk proteins 210 
used. Due to this heterogeneity, it is not possible to draw firm conclusions on the relative 211 
effects of milk proteins on the vascular function.  212 
We have identified three further RCTs: Petyaev et al. examined the impacts of WPL not only 213 
on BP, but vascular reactivity, using FMD
(34)
. They reported statistically significant 214 
improvements in FMD in the WPL group only (+2.6 %, p<0.05) compared to baseline. 215 
Arnberg et al. also evaluated the effects of intact whey, casein and semi-skimmed milk on 216 
arterial stiffness using PWV, however failed to show any changes in vascular function
(35)
. 217 
However Figueroa and colleagues reported favourable changes in augmentation index (AI: a 218 
measure of arterial stiffness) and brachial-PWV in both whey and casein groups combined 219 
with exercise, compared to the control group. It is of note that the randomisation may not 220 
have been adequate as the baseline values for both BP and arterial stiffness were different 221 
than the whey and casein groups which may have confounded the study (Table 2.). 222 
 223 
Short-term studies on vascular function 224 
Only four RCTs were conducted to evaluate the effects of milk proteins on vascular function 225 
in a postprandial setting
(32, 54-56)
. Pal and Ellis failed to show any acute effects of whey and 226 
casein ingestion with a meal in normotensive obese postmenopausal women on arterial 227 
stiffness measured by pulse wave analysis
(32)
. Likewise, Turpeinen et al. also did not observe 228 
any statistically significant change in arterial stiffness measured by PWV after acute ingestion 229 
of 25 mg lactotripeptides with 2 g plant sterol ester mixed in a milk drink in mildly 230 
hypertensive subjects
(54)
. However Ballard and colleagues reported significant improvements 231 
in arterial reactivity assessed by FMD (+4.3 %) at 120 min after ingestion compared with 232 
placebo corresponding time point, (p<0.05) in mildly hypertensive, overweight individuals 233 
after whey hydrolysate (5 g NOP-47) ingestion with water
(55)
. Mariotti et al. failed to report 234 
any significant effects of casein, whey or α-lactalbumin enriched whey protein on digital 235 
volume pulse (a measure of arterial stiffness)
(57)
 (Table 2.). 236 
Intriguingly, BP-lowering effects of milk proteins were not associated with changes in 237 
vascular function in the reviewed RCTs
(13)
 which is confirmed by emerging evidence on the 238 
relationship between BP and arterial stiffness. This suggests that the interaction between BP 239 
and arterial stiffness may be bi-directional
(58, 59)
 via complex interactions between different 240 
pathways such as inflammatory
(60, 61)
, hormonal (e.g. leptin, insulin)
(61-63)
 and disturbance in 241 
endothelial-derived mediators
(58)
. Therefore it is important to determine the effect on other 242 
mediators of risk that may indirectly affect BP.  243 
 244 
Glycaemic control 245 
Insulin has a range of biological actions within the human body
(64)
, not only has it a key 246 
regulatory role in metabolic energy disposal and storage in tissues, but it is responsible for 247 
cell growth and development
(65)
, ion transport
(66)
, and sympathetic nervous system activity
(67)
. 248 
In addition, insulin has haemodynamic activities such as increasing blood flow and cardiac 249 
output, probably via increased NO production
(64)
. Giugliano et al. demonstrated insulin 250 
release after an intravenous infusion of L-arginine resulted in improvements in FMD
(68)
. 251 
However Gates et al. showed an insulin-independent vasodilation after L-arginine 252 
administration
(69)
. Similarly, Ballard and colleagues reported an insulin-independent FMD 253 
improvement in response to the acute ingestion of a whey-derived peptide, NOP-47
(55)
.  254 
It is well established that food proteins and more specifically AAs acutely stimulate insulin 255 
secretion
(70)
 with several AAs possessing direct insulinotropic effects
(71, 72)
. Both whey and 256 
casein appear to increase insulin secretion, however to different extents
(73)
. This may be due 257 
to their effect on gastric emptying, absorption and kinetics, since the insulin responses seemed 258 
to correlate with the increase in plasma AA concentration after protein ingestion
(74)
. Likewise, 259 
hydrolysates appear to increase insulin production more than intact proteins
(75)
.  260 
It is not yet known how milk proteins exert their beneficial effects on glucose homeostasis, 261 
however, BCAAs, in particular, leucine, isoleucine, valine, lysine and threonine are shown to 262 
act as insulin secretagogues (inducing insulin secretion from pancreatic β-cells), with leucine 263 
reportedly having the greatest insulinotopic effect acutely
(76)
. This may be via the regulation 264 
of both ATP production (by metabolic oxidation and allosteric activation of glutamate 265 
dehydrogenase) and KATP activity
(77)
. Similarly, BCAA and particularly leucine, has been 266 
reported to activate the mammalian rapamycin (mTOR) pathway resulting in a higher incretin 267 
hormone (insulin, glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)) 268 
synthesis
(77, 78)
. GIP is also known as glucose-dependent insulinotropic peptide, synthesised 269 
by K cells found in the mucosa of the duodenum and jejunum in response to food ingestion, 270 
which may subsequently further induce insulin production
(79)
. While the effect of GIP appears 271 
to be more pronounced at normoglycaemic levels, GLP-1 is more active during 272 
hyperglycaemia
(79)
. Jakubowitz and Froy showed that whey protein drink increased GIP 273 
response (+80%) in healthy adults, yet a mixture of BBCA mimicking the supply of AA in 274 
whey protein, failed to exert the same effect
(80)
. Therefore they suggested that certain 275 
bioactive peptides and/or AAs deriving from whey protein during digestion may be 276 
responsible for this action
(80)
. GLP-1 is a potent antihyperglycemic hormone secreted by 277 
intestinal L cells
(79)
. Interestingly, it has been shown to possess cardioprotective effects, which 278 
may be further complemented by natriuretic and antioxidative stress on the kidneys leading to 279 
beneficial impacts on BP and vasculature
(81)
. This warrants further consideration in future 280 
research when the effects of milk proteins are assessed on the cardiovascular system. 281 
Additionally, GLP-1 was more pronounced in healthy subjects after whey consumption 282 
compared to casein or soya, however after 2 hours of ingestion the concertation of the 283 
hormone decreased, while it continued to increase after casein
(80, 82, 83)
. This may be explained 284 
by the different plasma kinetics of milk proteins. Two enzyme inhibitory peptides deriving 285 
from milk proteins have been associated with the beneficial effects on the glucose 286 
homeostasis: dipeptidyl peptidase-IV (DPP-IV) enzyme inhibitors and alpha-glucosidase 287 
(AG) enzyme inhibitors. Although DPP-IV plays several roles in different physiological 288 
processes, it has a distinct effect on glucose homeostasis by degrading incretin hormones: 289 
GLP-1 and GIP
(84)
. Whereas there is a definite lack of human studies examining the effects of 290 
DPP-IV inhibitory peptides deriving from milk proteins; some in silico (computer-aided), in 291 
vitro and limited animal studies suggesting a potential role in controlling glucose metabolism. 292 
Lacroix and Li-Chan proposed that casein appears to be a better source of DPP-IV inhibitory 293 
peptides than whey protein
(85)
. However, in vitro and in vivo studies suggest that whey protein 294 
may be equal or a better source of these inhibitory peptides (for review see
:(86)
). The AG 295 
enzyme is found in the brush border of the enterocytes in the small intestine and is responsible 296 
for the synthesis and breakdown of carbohydrate by cleaving glycosidic bonds in complex 297 
carbohydrates to produce monosaccharides. A potential therapy in type 2 diabetic patients 298 
could be to reduce the absorption of glucose by carbohydrate hydrolysing enzymes such as 299 
AG, which may also enhance and promote GLP-1 secretion
(87)
. A very limited number of in 300 
vitro studies demonstrated that AG inhibitory peptides may be derived from whey protein
(88, 
301 
89)
. This clearly warrants further research. 302 
 303 
Short-term studies on glycaemic control 304 
 305 
Milk proteins have been extensively investigated for their insulinotropic and glucose-lowering 306 
effects in healthy subjects
(73, 75, 82, 83, 90-99)
 and to a limited extent in individuals with 307 
suboptimal glucose control
(100-106)
. The dose varied significantly between studies from as little 308 
as 10 g
(92, 105, 106)
 to 51 g
(91)
. Milk proteins were administered on their own or with a meal or 309 
even served as pre-meals. Current evidence on the effects of whey protein on glucose control 310 
appears to be more promising than casein, furthermore it has been proposed that whey protein 311 
may be as effective at inducing insulin secretion as medication (sulfonylureas) prescribed for 312 
management of hyperglycaemia in type 2 diabetic patients
(80, 107)
 (Table 3.). Thus providing a 313 
rationale for individuals with impaired glucose control or for patients with T2DM (type 2 314 
diabetes mellitus) to consume whey protein prior to or with meals to control postprandial 315 
glucose metabolism. Future studies should examine the minimum dose at which whey protein 316 
exerts beneficial effects. Similarly due to the different timeframe by which milk proteins have 317 
an effect, longer postprandial trials (e.g. 24h) may provide important information on how 318 
casein could improve hyperglycaemia in individuals characterised by insulin resistance but 319 
with functional β-cells. 320 
 321 
Long-term studies on glycaemic control 322 
To best of our knowledge, only three studies have investigated the chronic supplementation of 323 
milk proteins, rather than milk or dairy products, on glycaemic control. Pal et al. examined 324 
the effects of whey and casein (2 x 27g/day for 12 weeks) in overweight and obese 325 
subjects
(96)
. Most subjects had borderline impaired glucose tolerance at baseline, but at the 326 
end of the intervention a reduced fasting insulin concentration was observed in the whey 327 
protein group compared with the control group (glucose), although no change in fasting 328 
glucose was reported. In another study, a whey fermentation product (malleable protein 329 
matrix, MPM) decreased fasting plasma glucose concentration after three months 330 
supplementation compared to the control group, which was more pronounced in individuals 331 
with impaired fasting glucose at baseline
(108)
. An acute-in-chronic study also reported a 332 
decrease in postprandial glucose response in whey group, which remained unchanged after the 333 
four-week supplementation period
(102)
 (Table 3.). 334 
 335 
Lipid metabolism 336 
Short-term studies on lipids 337 
Postprandial triacylglycerolaemia has been associated with markers of early atherosclerosis 338 
such as endothelial dysfunction and carotid media thickness
(109, 110)
 and is strongly influenced 339 
by the composition of a meal: including the quality and quantity of fat
(111, 112)
 and 340 
carbohydrate
(113, 114)
. In theory due to the insulinogenic effects of milk proteins, their 341 
consumption would be predicted to attenuate postprandial lipaemia, as insulin has an 342 
inhibitory effect on hormone-sensitive lipase and hepatic release of free fatty acid (FFA) and 343 
stimulatory effect on lipoprotein lipase which hydrolyses triacylglycerol for metabolism or 344 
storage. However evidence from postprandial RCT is limited. Postprandial investigations 345 
reported decrease in triacylglycerols (TAG) after both whey and casein ingestion in 346 
combination with a fat-rich meal in obese
(98)
 and individuals with T2DM
(103, 115)
, but showed 347 
no effect on TAG after acute consumption of whey protein
(99, 104)
. Free fatty acid also 348 
decreased after whey and casein ingestion in obese
(99)
 and T2DM patients
(104)
. It is of note that 349 
parameters of lipid metabolism such as low- and high-density lipoproteins and total 350 
cholesterol remain stable acutely
(116, 117)
.  351 
Recently an acute study reported that casein with a high fat, high energy meal, compared to 352 
whey protein and α-lactalbumin enriched whey protein, significantly reduced postprandial 353 
TAG and had a marked effect of chylomicron kinetics
(57)
. This could be due to the different 354 
physicochemical makeup of casein and whey protein, as casein forms a gel in the stomach 355 
influencing the rate of absorption and gastric emptying (Table 4.). 356 
 357 
Long-term studies on lipids 358 
To date, five chronic RCT, which examined the lipid lowering effects of milk proteins, have 359 
been identified. Three month supplementation of whey (2 x 25 g/day) and casein (2 x 25 360 
g/day) during an ad libitum weight regain diet after substantial diet-induced weight loss in 361 
healthy obese subjects resulted in no change in plasma lipids
(118)
. However whey protein 362 
isolate (2 x 27 g/day) significantly reduced fasting TAG, total cholesterol and LDL-363 
cholesterol after three months in overweight, obese individuals
(96)
. Another three month 364 
supplementation study with MPM (15 g/day protein in two daily servings of 150g yoghurt) 365 
reduced fasting TAG, which was more pronounced in subjects with elevated baseline 366 
TAG
(108)
. In a six week study casein (35 g/day) also reduced total cholesterol in 367 
hypercholesterolemic subjects
(119)
. Petyaev et al. reported a decrease in LDL-cholesterol, 368 
TAG and TC in their pilot study
(34)
 (Table 4.). The limited evidence suggests that milk 369 
proteins have a beneficial impact on fasted lipids, although further studies are required. 370 
However it is not clear as to possible mechanisms of action although insulin may play a role. 371 
In vitro studies suggest that milk proteins and BCAA inhibit expression of genes involved in 372 
intestinal fatty acid and cholesterol absorption and synthesis
(120)
. Whey has been shown to 373 
induce urinary excretion of tricarboxylic acid cycle (TCA) compounds such as citric acid and 374 
succinic acid in rats, which are substrates for lipogenesis, suggesting an increased catabolic 375 
state (e.g. lipolysis) and reduced lipid accretion compared to casein
(121)
. This could be a 376 
possible mechanism of lipid reduction. Similarly, in another metabolic study conducted in 377 
humans, cheese (casein) appeared to induce lowering of urinary citrate
(122)
, which suggests 378 
that cheese consumption affects the TCA cycle. Additionally, microbiota-related metabolite, 379 
hippuric acid was significantly higher in the cheese group, than in the milk, implying a 380 
stimulation of gut bacteria activity. The enhanced bacterial activity also resulted in higher 381 
short-chain fatty acids (SCFA)
(122)
, which have been proposed as key regulatory metabolites 382 
in lipid metabolism
(123)
. This effect may be due to the cheese matrix rather than the casein per 383 
se. An in vivo study proposed another potential mechanism of action through decreased lipid 384 
infiltration into the liver in rats with non-alcoholic fatty liver
(124)
. Another possible putative 385 
mechanism is increased fat oxidation. Lorenzen et al. demonstrated an increased lipid 386 
oxidation after acute casein consumption compared to whey
(125)
. They speculated that it may 387 
be due to lower insulin secretion after casein consumption relative to whey since insulin 388 
downregulates lipid oxidation. However insulin was not measured in the study and this 389 
mechanism could not be confirmed. The same research group examined the effects of dairy 390 
Ca on lipid metabolism in conjunction with a low and high fat diet during 10 days
(126)
. They 391 
found that dairy Ca attenuates the increase in total and LDL-cholesterol, without affecting the 392 
rise in HDL-cholesterol. This observed phenomenon may be due to the formation of insoluble 393 
Ca-fatty acid soaps and/or the production of hydrophobe aggregation with bile and with other 394 
fatty acids
(126-128)
.  395 
 396 
Inflammation and oxidative stress  397 
Inflammation and oxidative stress are chronic conditions which contribute to many diseases 398 
such as obesity
(129)
, T2DM
(130)
 and CVD
(131)
. Different dietary components have an impact on 399 
low-grade inflammation
(132)
, however there is a lack of RCTs evaluating the acute and chronic 400 
consumption of milk proteins on inflammation or oxidative stress with inconsistent outcomes.  401 
Long-term studies on inflammation and oxidative stress 402 
A recent meta-analysis evaluated the effects of chronic consumption of whey protein and 403 
hydrolysate on C-reactive protein (CRP), a systemic inflammatory marker
(133)
. Nine RCTs 404 
were included which showed a small, non-significant reduction in CRP 0.42mg/L (95% CI 405 
−0.96, 0.13). Sub-group analyses suggested that >20 g/day may be more effective, and elevated 406 
baseline CRP level (≥3 mg/L) could be more responsive to whey or whey peptides 407 
consumption(133). Similarly, Arnberg et al. reported no change in CRP in adolescence after whey, 408 
casein or skim milk consumption for 12 weeks(35). 409 
Interleukin (IL)-6, IL-8 and tumour necrosis factor (TNF)-α are also recognised inflammatory 410 
markers, which induce CRP. Pal and Ellis failed to observe significant changes in these 411 
inflammatory markers (2 x 27g whey or casein or glucose for 12 weeks) in overweight 412 
individuals(33). However Sugawara et al. reported decreased level of IL-6, IL-8 and TNF-α in 413 
patients with chronic obstructive pulmonary disease after whey intervention compared with 414 
control group(134). Likewise, IL-6 and TNF-α were decreased after lactoferrin consumption for six 415 
months in postmenopausal women(135). Similarly Hirota et al. reported decreased levels of TNF-α 416 
in mildly hypertensive subjects fed with the casein-derived lactotripeptides(46) (Table 5.). 417 
 418 
Long-term studies on inflammation and oxidative stress 419 
Pal and Ellis, also reported no change in IL-6, IL-8 and TNF-α in a postprandial study 420 
investigating whey and casein
(32)
. Likewise, a whey-derived peptide, NOP-47, also failed to 421 
change the level of serum cytokines (TNF-α, IK-6, IL-8, monocyte chemoattractant protein-1, 422 
vascular endothelial growth factor, soluble E-selectin, soluble vascular cell adhesion 423 
molecule-1) and chemokines
(56)
. However consumption of a cake containing whey protein 424 
after exhaustive cycling in nine subjects reported reduced levels of CRP and IL-6 by 46% and 425 
50%, respectively
(136)
. Holmer-Jensen et al. assessed the postprandial effects of whey protein, 426 
casein, gluten and cod on low-grade inflammatory markers (monocyte chemotactic protein-1 427 
(MCP-1), CC chemokine ligand-5 (CCL5/RANTES)) in conjunction with a high fat meal
(137)
. 428 
They reported that all meals increased CCL//RANTES, however the smallest increase was 429 
observed after the whey protein meal. MCP-1 was initially suppressed after all meals, and the 430 
meal containing whey protein induced the smallest overall postprandial suppression
(137)
 431 
(Table 5.). 432 
The mechanism of action of milk proteins on oxidative stress and inflammation are unclear 433 
but Ca may supresses the pro-inflammatory and reactive oxygen species production in 434 
vitro
(138)
. Interestingly, the milk protein-derived inhibitors of the angiotensin-I-converting 435 
enzyme may also be involved in the anti-inflammatory process
(139)
.  436 
 437 
Conclusion and implication for future studies 438 
Taken together, there is a growing number of RCTs which suggest that casein and whey 439 
protein may have a role in cardiometabolic health. Studies focussed on reducing chronic 440 
disease risk factors such as hypertension and dysregulated lipid/glucose metabolism by non-441 
pharmacological, dietary strategies will have significant implications not only for social and 442 
economic welfare, but for the healthcare system.  443 
Due to the different physicochemical makeup of casein and whey protein, they may exert 444 
differential effects in vivo in humans. Notably, manufacturing may play a significant role in 445 
the physiological effects of milk proteins, however future studies should investigate which 446 
processing method results in more bioactive effects. There is inconclusive evidence on the 447 
relative impacts of milk proteins on diurnal BP and vascular function, yet there appears to be 448 
strong evidence on the insulinotropic impacts of dairy proteins, owing to the specific AA 449 
composition such as BCAA. They also appear to play a beneficial role in lipid homeostasis 450 
(Table 1.). Nevertheless the mechanism underlying the action of dairy proteins on the 451 
cardiometabolic health warrants further research.  452 
The incorporation of a meal enriched with protein in the habitual diet may result in the 453 
improvement of cardiometabolic health as well as the prevention of developing 454 
cardiometabolic diseases. Additionally, in contrast with pharmacological antihypertensive 455 
treatments, food-derived proteins have not been shown to cause any side-effects or 456 
hypotension, making them safe to consume by individuals with a variety of other disease 457 
conditions. After careful consideration of the available evidence and knowledge gaps, we 458 
have conducted two double-blind, controlled, cross-over studies aiming to compare the 459 
chronic (n=38) and postprandial (n=27) impacts of whey protein isolate (2 x 28 g) and Ca-460 
caseinate (2 x 28 g) with control (2 x 26 g, maltodextrin) on vascular function, BP, markers of 461 
insulin resistance, lipid metabolism and inflammatory status in men and women with mild 462 
hypertension (≥120/80 mmHg). These studies aim to provide valuable information on the 463 
relative effects of milk proteins on blood pressure and on detailed aspects of vascular function 464 
compared with maltodextrin. These trials will further our knowledge of whether milk proteins 465 
have significant influences as health-promoting food components and whether the public as 466 
well as the food industry could benefit from it. The results from these studies are likely to be 467 
available in mid-2016. 468 
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Reference Subjects (n) 
Study design 
and duration 
Treatment (g) Comparison Treatment effect 
LONG-TERM           
Petyaev et al.
(34)
 
Prehypertensive 
(40) 
Pilot, 4 
weeks  
Whey protein isolate (70 
mg) embedded into 
lycopene micelles (7 mg) 
Whey protein isolate, 
lycopene and placebo 
↓BP 
Arnberg et al.
(35)
 
Overweight 
adolescents 
(193) 
12 weeks 
Casein (35g/L), whey 
protein (35g/L) and 
skimmed milk (1 litre) 
Water, pretest control group 
↓bBP and cDBP in casein group, 
↑cDBP, bSBP and cSBP in whey 
group 
Figueroa et al.
(36)
 
Obese women 
(33) 
4 weeks  Casein, whey protein Carbohydrate 
↓bSBP and aSBP in casein and 
whey groups 
SHORT-TERM           
Teunissen-Beekman et 
al.
(40)
 
Overweight or 
obese (48) 
240 mins 
Milk protein, pea protein, 
egg-white protein 
Maltodextrin 
↓BP milk and pea protein groups 
compared to egg-white protein 
group 
↑, Increase; ↓, Decrease; BP, blood pressure; bBP, brachial blood pressure; cBP, central blood pressure; DBP; diastolic blood  pressure; SBP, systolic blood 
pressure 
 
 
 
 
 
 
 
 
 
 
 
     
Table 1. Impacts of milk proteins on blood pressure.   
Reference Subjects (n) 
Study design 
and duration 
Treatment (g) Comparison Treatment effect 
LONG-TERM           
Petyaev et al.
(34)
 
Prehypertensive 
(40) 
Pilot, 4 
weeks  
Whey protein isolate (70 
mg) embedded into 
lycopene micelles (7 mg) 
Whey protein isolate, 
lycopene and placebo 
↑FMD 
Arnberg et al.
(35)
 
Overweight 
adolescents 
(193) 
12 weeks 
Casein (35g/L), whey 
protein (35g/L) and 
skimmed milk (1 litre) 
Water, pretest control group ↔ 
SHORT-TERM           
Mariott
(57)
 
Overweight men 
(10) 
360 mins Casein 
Whey protein isolate, α-
lactalbumin-enriched whey 
protein 
↔ 
FMD, flow-mediated dilation, ↑, Increase; ↔, no effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Table 2. Impacts of milk proteins on vascular function 
Reference Subjects (n) 
Study design 
and duration 
Treatment (g) Comparison Treatment effect 
SHORT-TERM           
Nilsson et al.
(73)
 Healthy (12) 120 mins WP (18.2 g) 
White-wheat bread, milk, cod, 
cheese, gluten-low, gluten-
high 
↑Insulin response, ↑GIP, 
↔GLP-1 
Calbet et al.
(75)
 Healthy (6) 120 mins HC (36 g) Intact casein ↑GIP 
Hall et al.
(82)
 Healthy (9) 180 mins WP (48 g) Casein ↑GLP-1 
Veldhorst et al.
(83)
 Healthy (25) 180 mins WP (10 and 25%) Casein, soy ↑GLP-1 
Petersen et al.
(90)
 Healthy (10) 120 mins WP (20 g) Glucose ↓Glucose response 
Pal and Ellis
(91)
 
Healthy men 
(22) 
240 mins WP (50.8 g) Turkey, egg, tuna 
↓Glucose response,                          
↑Insulin response 
Akhavan et al.
(92)
 Healthy (10) 230 mins WP as pre-meal (10-20 g) Glucose, water 
↓Glucose response,                         
↑GLP-1, ↑GIP 
Akhavan et al.
(93)
 Healthy (16/21) 170 mins WP as pre-meal (10-40 g) Water ↓Glucose response 
Acheson et al.
(94)
 Healthy (23) 330  mins WPI (50 % of diet) Casein, soy, glucose ↑Insulin response 
Morifuji et al.
(95)
 Healthy (10) 120 mins WPH (86,9%) WP, soy, soy hydrolysate ↑Insulin response 
Nilsson et al.
(97)
 Healthy (12) 120 mins WP (18 g) Glucose, amino acids ↔GLP-1 
Holmer-Jensen et al.
(98) 
 Obese (11) 480 mins WPI + fat-rich meal (45 g) Casein and gluten ↓GIP 
Holmer-Jensen et al.
(99) 
 Obese (12) 480 mins WPI + fat-rich meal (45 g) WP specific fractions ↔GLP-1 
Frid et al.
(100)
 T2D (14) 240 mins WP (27.6 g) Ham (96 g ) + lactose (5.3 g) 
↓Glucose response,                          
↑Insulin response 
Ma et al.
(101)
 T2D (8) 300 mins WP as pre-meal (55 g) WP in main meal ↑Insulin and incretin response 
Ma et al.
(102)
 T2D (7) 240 mins WPI (25 g) 'diet' drink ↓Glucose response 
Mortensen et al.
(103)
 T2D (12) 480 mins WPI + fat-rich meal (45 g) Casein, gluten, cod ↔GLP-1, ↓GIP 
Mortensen et al.
(104)
 T2D (12) 480 mins WPI + fat-rich meal (45 g) WP specific fractions ↔GLP-1 
Jonker et al.
(105)
 T2D (13) 250 mins CH (12 g) CH (0 g) ↑Insulin response 
Table 3. Impacts of milk proteins on glycaemic control. 
Geerts et al.
(106)
 T2D (36) 240 mins CH (12 g) Intact casein ↓Glucose response 
LONG-TERM           
Pal et al.
(96)
 
Overweight and 
obese (70) 
12 weeks WPI (2x27 g/d) Glucose ↑Fasting insulin + HOMA-IR 
Ma et al.
(102)
 T2D (7) 4 weeks WPI (25 g) 'diet' drink ↓Glucose response 
Gouni-Berthold et al.
(108)
 MS (180) 12 weeks Whey MPM (15.3g) Placebo ↓Glucose response 
↑, Increase; ↓, Decrease; ↔, no effect; CH, casein hydrolysate; D, day; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; 
HC; hydrolysed casein; HOMA-IR, homeostasis model assessment of insulin resistance; MS; metabolic syndrome; T2D, type-2 diebetes; Whey MPM, whey 
malleable protein matrix; WP, whey protein; WPH,  whey protein hydrolysate;WPI, whey protein isolate. 
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Reference Subjects (n) 
Study design 
and duration 
Treatment (g) Comparison Treatment effect 
SHORT-TERM           
Brader et al.
(115)
 T2D (11) 480 mins 
Casein combined with 
carbohydrates and a fat-rich 
meal (45 g) 
Control meal, control 
meal+carbohydrate, control 
meal+casein 
 ↓TAG concentration in 
chylomicron-rich fraction 
Holmer-Jensen et al.
(98) 
 Obese (11) 480 mins 
WPI + fat-rich meal                
(45 g) 
Cod and gluten 
↓TAG response, ↓TAG 
concentration in chylomicron-
rich fraction, ↓FFA 
Holmer-Jensen et al.
(99) 
 Obese (12) 480 mins WPI + fat-rich meal (45 g) WP specific fractions ↔TAG response 
Mortensen et al.
(103)
 T2D (12) 480 mins WPI + fat-rich meal (45 g) Casein, gluten, cod ↓TAG response, ↓FFA 
Mortensen et al.
(104)
 T2D (12) 480 mins WPI + fat-rich meal (45 g) WP specific fractions ↔TAG response 
LONG-TERM           
Pal et al.
(96)
 
Overweight and 
obese (70) 
12 weeks WPI (2x27 g/d) Glucose ↓Fasting TAG, ↓TC, ↓LDL-c 
Weisse et al.
(119)
 
Hyper-
cholesterolemic 
(43) 
6 weeks Casein (35 g/d) Baseline ↓TC 
Claessens et al.
(118)
 Obese (48) 12 weeks WP (2x25 g/d) Casein ↔fasting lipids 
Petyaev et al.
(34)
 
Prehypertensive 
(40) 
Pilot,                     
4 weeks  
Whey protein isolate (70 
mg) embedded into 
lycopene micelles (7 mg) 
Whey protein isolate, 
lycopene and placebo 
↓TC, ↓TAG, ↓LDL-c, ↑HDL 
Gouni-Berthold et al.
(108)
 MS (180) 12 weeks Whey MPM (15.3g) Placebo ↓TAG 
↑, Increase; ↓, Decrease; ↔, no effect; CH, casein hydrolysate; D, day;  FFA, free fatty acids; HC; hydrolysed casein; HDL-c, high-denisty lipoprotein 
cholesterol; LDL-c, low-density lipoprotein cholesterol; MS; metabolic syndrome; T2D, type-2 diebetes; TAG, triacylglycerol; TC, total cholesterol; Whey 
MPM, whey malleable protein matrix; WP, whey protein; WPH,  whey protein hydrolysate;WPI, whey protein isolate. 
      
Table 4. Impacts of milk proteins on lipid metabolism. 
Reference Subjects (n) 
Study design 
and duration 
Treatment (g) Comparison Treatment effect 
LONG-TERM           
Sugawara et al.
(134) 
 COPD (36) 12 weeks WP (20 g) 0 g WP ↓CRP, ↓IL-6,↓IL-8, ↓TNF-α 
Bharadwaj et al.
(135) 
 
Post-menopausal 
women (38) 
24 weeks 
Ribonuclease-enriched 
lactoferrin                              
(2 × 125 mg/d) 
Placebo ↓IL-6, ↓TNF-α 
Arnberg et al.
(35)
 
Overweight 
adolescents 
(193) 
12 weeks 
Casein (35g/L), whey 
protein (35g/L)  
Water, pretest control group ↑CRP 
Pal and Ellis
(33)
 Overweight (70) 12 weeks 
WPI (54 g),                     
Casein (54 g) 
Glucose ↔CRP, ↔IL-6, ↔TNF-α 
Hirota et al.
(46)
 
Mild hyper-
tensives (25) 
1 week 
VPP (3.42 mg),                     
IPP (3.87 mg) 
Baseline ↔CRP, ↓TNF-α 
SHORT-TERM           
Pal and Ellis
(32)
 
Overweight 
postmenopausal 
women (20) 
480 mins 
WPI (45 g),                          
Casein (45 g) 
Glucose ↔CRP, ↔IL-6, ↔TNF-α 
Ballard et al.
(56)
 Healthy (20) 120 mins 
Whey-derived peptide 
(NOP-47, 5 g) 
Placebo 
↔CRP, ↔IL-6, ↔IL-8, ↔TNF-
α 
Kerasioti et al.
(136)
 Healthy men (9) 48 h  
WP (0.26 g 
protein/kg BW/h) 
Placebo ↓CRP, ↓IL-6, ↑IL-10 
Holmer-Jensen et al.
(137)
 Obese (11) 240 mins WP + high-fat meal 
Casein, cod and gluten + high-
fat meal 
↓CCL5/RANTES, ↑MCP-1 
↑, Increase; ↓, Decrease; ↔, no effect; BW, body weight; CCL, CC chemokine ligand-5; CH, casein hydrolysate; COPD, chronic obstructive pulmonary 
disease; CRP, C-reactive protein; D, day;  IL, interleukin; IPP, Isoleucine-Proline-Proline; MCP-1, monocyte chemotactic protein-1; TNF, tumor necrosis 
factor; VPP, Valine-Proline-Proine; Whey MPM, whey malleable protein matrix; WP, whey protein; WPH,  whey protein hydrolysate;WPI, whey protein 
isolate. 
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Table 5. Impacts of milk proteins on inflammation and oxidative stress. 
